amg-319
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2011 (NCT01300026)
Timeline
Indications
Studied for
- Hematologic Neoplasms · Phase 1
- Hematology · Phase 1
- Human papillomavirus 16 · Phase 2
- Leukemia · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Lymphoma · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Lymphoma, T-Cell · Phase 1
- Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 2
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
C[C@H](Nc1ncnc2[nH]cnc12)c1cc2ccc(F)cc2nc1-c1ccccn1- Mol. weight
- 385.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4303596 ↗
- ChEMBLCHEMBL3545048 ↗
Also known as
- amg 319
- amg 319
- amg-319
- amg-319
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02540928 | Phase 2 | Oct 1, 2015 | Cancer Research UK |
| NCT01300026 | Phase 1 | Apr 1, 2011 | Amgen |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Amgen | For profit | 1 | 1 | 1 | 2011 |
| Cancer Research UK | Academic/Hospital | 1 | 1 | 1 | 2015 |
2 organizations
Page 1 / 1